Since its creation, the 340B Drug Pricing Program has been assisting hospitals and health care providers who meet certain criteria in purchasing outpatient drugs at discounted prices and thus enabling them to maximize use of funds in caring for underserved populations. However, recent developments by Eli Lilly have made compliance even harder than before, putting additional strain on hospital budgets and operations. As other pharmaceutical companies continue adopting the same approach, healthcare facilities face mounting pressure to adapt and enhance their compliance strategies.
This blog will discuss Lilly's new 340B claims data policy, reasons for which hospitals are fearful of the loss of drug discounts, how the development may affect compliance in the healthcare sector in general and what healthcare facilities need to be prepared for going forward.
How Lilly's New 340B Reporting Requirements Are Changing Hospital Operations
Recent changes to the 340B Drug Pricing Program are not limited to compliance with regular reporting requirements. Through the condition of submission of the claims data for discounted pricing, drug makers are redefining the way hospitals manage their pharmacies and compliance procedures. It is both an effort toward increased transparency as well as an added burden for healthcare facilities.
Why Lilly Expanded Its 340B Claims Data Requirements
The expanded claims reporting policy was launched by Lilly to address the issue of duplication of discounts and any abuse of the program. According to Lilly, it is possible that drugs that fall within the purview of both the 340B Program and the Inflation Reduction Act pricing policy of Medicare will be getting duplicate discounts. Furthermore, pharmaceutical companies have also raised concerns regarding duplicate rebates between Medicaid programs and diversion of the discount drugs to ineligible patients.
Under this expanded policy of Lilly, it is essential for participating hospitals to provide pharmacy and medical claims data through the 340B ESP portal according to the stipulated timelines. Failure to do so means that the hospital will be deprived of discounts on the drugs and will be forced to pay for them at the higher wholesale acquisition cost.
What Hospitals Must Submit Under the New Policy
The new guidelines regarding reporting also go much further than prior guidelines which were mainly concerned about reporting related to contract pharmacies. In this regard, hospitals are now required to provide full claims details relating to pharmacy claims made by them, and these details include many different information fields such as medicine quantity, refill details, supply duration, medical modifiers, etc.
The timeframes provided for reporting leave no place for procrastination either. Most outpatient drugs claims need to be reported within 45 days from the date of dispensing, while some specialty drugs that need injections or infusions will be reported in 60 days after dispensing.
Immediate Financial Consequences for Non-Compliant Hospitals
Failure by hospitals to meet the reporting obligations set forth by Lilly has financial repercussions that come into effect immediately. This is because such hospitals are not able to access 340B pricing, meaning that they have to pay for drugs through wholesale acquisition cost instead of lower prices, which translates to higher pharmaceutical costs.
To some hospitals which are already running on very little margins, this will translate to lower funds that can be allocated for their community health initiatives, unpaid services, and other clinical services.
|
Requirement |
Impact on Hospitals |
|
Detailed claims reporting |
Increased administrative workload |
|
45-60 day submission deadlines |
Faster reporting cycles required |
|
Loss of 340B pricing for non-compliance |
Higher drug acquisition costs |
|
Expanded in-house pharmacy reporting |
Greater technology and staffing needs |
Growing Industry Response and Regulatory Uncertainty
The issue of Lilly’s policy on reporting has become an issue that goes beyond this policy alone to become a wider issue about the future of the 340B Program. This is because there are different views on the issue by various stakeholders.
Why Hospital Organizations Oppose the New Requirements
Healthcare providers claim that the increased reporting requirement imposes an additional administrative task on them, in addition to exposing confidential patient information. 340B Health believes that hospitals are now being forced to send millions of claim lines directly to manufacturers despite the lack of any regulatory approval.
Similarly, the American Hospital Association has also denounced the new policy and called upon federal agencies to take action. Hospitals feel that the manufacturer should not be allowed to impose these reporting requirements unilaterally, which can weaken the statutory price protections under the 340B Program.
HRSA's Position Remains Unclear
The Health Resources and Services Administration (HRSA), which runs the 340B program, has not yet made an official stance on the extended reporting requirements set forth by Lilly. Although HRSA has stated that they are considering the matter, hospitals currently have no regulatory guidance at all.
This ambiguity leaves hospitals in a tricky situation. Organizations may either comply with the demand of the manufacturer to ensure discounts, or wait until there might be a clarification of regulations, which will change the compliance requirements in the future. Legal professionals believe that this problem can be solved through litigation at some point.
Other Drug Manufacturers Are Following the Same Path
It is not the case anymore that Lilly alone among pharma companies demands expanded claims reporting. There have been reports that pharma companies such as Novo Nordisk, AstraZenica, and Bristol Myers Squibb have also started requiring similar claims reporting for some of their 340B products.
The above information shows that it may become a common practice among the industry irrespective of the outcome of any legal dispute. There will be an increasing compliance burden as many more manufacturers adopt the same reporting practices.
|
Manufacturer Trend |
Potential Provider Impact |
|
Expanded claims reporting |
Higher compliance workload |
|
Multiple reporting platforms |
Increased operational complexity |
|
Discount eligibility tied to reporting |
Greater financial risk |
|
Broader manufacturer adoption |
Industry-wide process changes |
Preparing Hospitals for the Future of 340B Compliance
Irrespective of any decisions made in court in the future, there are practical measures that could be taken by health care organizations to improve compliance process management. The current reporting requirements may just be the beginning of other structural changes to the 340B Program.
Strengthening Internal Compliance and Data Management
The hospital needs to determine how pharmacy, billing, compliance, and IT staff will efficiently match each medication dispensation to qualifying visits by patients, the prescribing physician and payer information. As reporting continues to increase, there is going to be a need for integrated data management systems.
It would also be prudent for the organizations to conduct a workflow review and discover any gaps that exist in reporting processes in order to enhance documentation and ensure proper coordination between departments handling claims submissions.
Alternative Solutions Proposed by the Healthcare Industry
Instead of mandating that hospitals file extensive claims to individual manufacturers separately, healthcare agencies have recommended setting up a third-party clearinghouse under the supervision of the federal government. The system would help identify any duplicate discounts and diversion issues while keeping the burden on the side of administration and preserving the confidentiality of patient information intact.
Advocates of this approach claim that it would help enhance consistency and minimize reporting redundancies. It is yet unclear whether the policymakers at the federal level will go for this idea, but it is still receiving considerable support from the providers' side.
What Healthcare Providers Should Watch Going Forward
Another important development in this regard is HRSA’s plan for a 340B rebate model that can dramatically alter the way hospitals receive their rebates from the 340B program. A rebate system requires the initial purchase of the drug at the full cost, followed by a reimbursement through claims.
If this model takes effect, it will put more strain on the cash flows of the hospitals, as well as make the claim reporting process more important than ever. It is crucial for healthcare organizations to stay tuned to the regulatory developments and manufacturer policies in 2026 and afterwards.
The changes in Lilly’s expanded 340B reporting requirements are a clear indication of the changes that the pharmaceutical manufacturers have undergone when it comes to the management of discount eligibility. Although the manufacturers feel that this will protect them from any duplications within the program, hospitals feel that it is going to create extra costs in administration.
As more pharmaceutical manufacturers adopt such reporting policies and as HRSA works on expanding further into reforming the same, healthcare organizations need to focus on developing compliance management and data management capabilities to ensure that they cope with the evolving complexities.
Follow The Fino Partners for practical insights on accounting, taxation, bookkeeping, healthcare finance, regulatory updates, and business trends that help organizations make informed financial decisions. Explore our expert resources to stay ahead of changing compliance requirements and industry developments.
